Overview
- Species: Other
- Additional Attributes: HyStem®/hyaluronic acid
- Specific Attributes: steril
PEGSSDA
Cat.-Nr.: GS755-2EA
Description
PEGSSDA allows researchers to quickly and gently dissolve HyStem® hydrogels non-enzymatically, thereby easily recovering cells or spheroids either grown on top or within the hydrogel. PEGSSDA contains two internal disulfide bonds which are rapidly reduced with small amounts of reducing agent (such as N-acetyl cysteine or glutathione), causing gel liquefaction.
PEGSSDA is a pentablock PEGDA molecule composed of four PEG molecules (MW 2000 Da) and two interdigitated disulfide bonds. Only the external PEG molecules are acrylated. The final molecular weight is approximately 8500 Da. Like PEGDA, PEGSSDA is a thiol-reactive crosslinker that covalently reacts with the thiol groups in Glycosil®, HyStem, Heprasil®, and Gelin-S® to form viscoelastic hydrogels. PEGSSDA is lyophilized in water.
Simply replace Extralink or Extralink-Lite with PEGSSDA to use in HyStem kits.
Bulk non-sterile PEGSSDA is also available upon request.
SUPPLIER:
Advanced BioMatrix
STATUS:
In Stock
SIZE:
2 x 0,5 ml
References
- References for HyStem®:
- Maloney, E. et al.Immersion Bioprinting of Tumor Organoids in Multi-Well Plates for Increasing Chemotherapy Screening Throughput. Micromachines 11, 208 (2020).
- Gaetani, R., et al. (2015) Epicardial application of cardiac progenitor cells in a 3D-printed gelatin/hyaluronic acid patch preserves cardiac function after myocardial infarction. Biomaterials 61: 339-348. PMID: 17335875.
- Prestwich, G.D., et al. (2007) 3-D culture in synthetic extracellular matrices: new tissue models for drug toxicology and cancer drug discovery. Adv Enzyme Regul 47: 196-207. PMID: 17335875.
- Shu, X.Z., et al. (2006) Synthesis and evaluation of injectable, in situ crosslinkable synthetic extracellular matrices for tissue engineering. J Biomed Mater Res A 79: 901-912. PMID: 16941590.
- Shu, X.Z., et al. (2003) Disulfide-crosslinked hyaluronan-gelatin hydrogel films: a covalent mimic of the extracellular matrix for in vitro cell growth. Biomaterials 24: 3825-3834. PMID: 12818555.
- Cai, et al. (2005) Injectable glycosaminoglycan hydrogels for controlled release of human basic fibroblast growth factor.Biomaterials, 26, 6054-6067.
- B. Pike, et al. (2006) Heparin-regulated release of growth factors in vitro and angiogenic response in vivo to implanted hyaluronan hydrogels containing VEGF and bFGF. Biomaterials, 27, 5242–5251.
- D. Prestwich, et al. (2007) 3-D Culture in Synthetic Extracellular Matrices: New Tissue Models for Drug Toxicology and Cancer Drug Discovery. invited, Adv. Enz. Res., in press (2007).
- Z. Shu, et al, (2006) Synthesis and Evaluation of Injectable, In Situ Crosslinkable Synthetic Extracellular Matrices (sECMs) for Tissue Engineering. J. Biomed Mater. Res. A, 79A(4), 901-912.
- Shu, X.Z., et al. (2004) In situ crosslinkable hyaluronan hydrogels for tissue engineering. Biomaterials 25: 1339-1348. PMID: 14643608.
- Mehra, T.D., et al. (2006) Molecular stenting with a crosslinked hyaluronan derivative inhibits collagen gel contraction. J Invest Dermatol 126: 2202-2209. PMID: 16741511.
- Shu, X.Z., et al. (2004) Attachment and spreading of fibroblasts on an RGD peptide-modified injectable hyaluronan hydrogel. J Biomed Mater Res A 68: 365-375. PMID: 14704979.
- Ghosh, K., et al. (2007) Cell adaptation to a physiologically relevant ECM mimic with different viscoelastic properties. Biomaterials 28: 671-679. PMID: 17049594.
Lifeink® 200; Type I Collagen Bioink